[Current cost analysis in the management of diabetes mellitus].
This article considers the costs that arise in the context of the medical management of diabetes mellitus (DM) under different therapeutic regimes. The following evaluations were used in assessing these costs: the LIVE-KK study, a routine data analysis, the LIVE-SPP study, a medical practice data analysis and the LIVE-DE study (a medical practice data survey). Overall the available information indicates that the total cost of the treatment based on insulin gargine is comparable to that incurred with the NPH insulin-based treatment. The treatment showing a medical advantage is thus also the most cost-effective treatment. Another favourable aspect is that patients remain on the combination treatment of insulin glargine with oral antidiabetic drugs longer than is the case with the combination treatment of NPH insulin plus oral antidiabetics.
Oberender
P
P
Oberender & Partner, Unternehmensberatung im Gesundheitswesen, Bayreuth. peter.oberender@oberender-online.de
D003365:Costs and Cost Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D005858:Germany; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000191:economics; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000191:economics* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine